title: Oral administration of RU 486 and 9-methylene PGE2 for termination of early pregnancy.
abstract: It has been shown that the antiprogestin RU 486 increases the sensitivity of the early pregnant human uterus to the stimulatory action of prostaglandin E analogues administered vaginally or intramuscularly. To examine if RU 486 also increases uterine sensitivity to a PGE analogue given orally, two investigative approaches were used in the present study: 1) direct registration of uterine contractions before and after administration of 9-methylene PGE2 in untreated and RU-486-treated early pregnant women; and 2) an efficacy trial involving treatment of pregnant women (amenorrhea of 49 days or less) with 25 mg RU 486 twice daily for three or four days followed by 2.5, 5.0 or 10 mg 9-methylene PGE2, or 600 mg RU486 followed by 10 mg 9-methylene PGE2 administered on day 3 and 4. The results showed that oral 9-methylene PGE2 had a clear stimulatory effect on uterine contractility which was further increased by pretreatment with RU 486. Following 2.5, 5.0 or 10.0 mg 9-methylene PGE2, the frequency of complete abortion was the same, or approximately 80%. The success rate is higher than that generally reported for RU 486 treatment alone. If 600 mg RU 486 was complemented with 10 mg 9-methylene PGE2 administered on both days 3 and 4, the frequency of complete abortion increased to 95%. Side effects were of a mild nature and generally occurred following administration of 9-methylene PGE2. The results of the present study indicate that a combined treatment based on oral administration of both the antiprogestin and the prostaglandin analogue can be developed into a highly effective and simple method to terminate early pregnancy.
authors.affiliation: Department of Obstetrics and Gynecology, Karolinska Hospital, Stockholm, Sweden.
authors.forename: M L
authors.initials: ML
authors.lastname: Swahn
authors.forename: C
authors.initials: C
authors.lastname: Gottlieb
authors.forename: K
authors.initials: K
authors.lastname: Green
authors.forename: M
authors.initials: M
authors.lastname: Bygdeman
mesh_terms: D015064:16,16-Dimethylprostaglandin E2 / Q000008:administration & dosage* / Q000009:adverse effects / Q000031:analogs & derivatives / Q000097:blood; D000019:Abortifacient Agents; D000028:Abortion, Induced / Q000379:methods*; D000284:Administration, Oral; D006063:Chorionic Gonadotropin / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage* / Q000009:adverse effects; D011247:Pregnancy; D011261:Pregnancy Trimester, First; D011372:Progestins / Q000037:antagonists & inhibitors*; D011459:Prostaglandins E, Synthetic / Q000008:administration & dosage*; D014590:Uterine Contraction / Q000187:drug effects
chemical_list: D000019:Abortifacient Agents; D006063:Chorionic Gonadotropin; D006454:Hemoglobins; D011372:Progestins; D011459:Prostaglandins E, Synthetic; C025505:meteneprost; D015735:Mifepristone; D015064:16,16-Dimethylprostaglandin E2